Strata Select™, EpiSwitch® CiRT for Immunotherapy Management
Immunotherapy has transformed cancer treatment, but response rates remain highly variable. Accurate biomarker-driven stratification is essential to predict which patients are most likely to benefit. The Strata Select™ test integrates multiple biomarkers to generate an Immunotherapy Response Score (IRS), guiding treatment decisions for anti-PD-1/PD-L1 therapies across all tumor types. Key components include:
- PD-L1 gene expression
- PD-L1 immunohistochemistry (IHC)
- Tumor mutational burden (TMB) across 437 genes
- Microsatellite instability (MSI)
PD-1, expressed on T-cells, functions as an immune checkpoint that promotes self-tolerance and tumor immune evasion when bound to PD-L1, which is often overexpressed on tumor cells. Anti-PD-1/PD-L1 therapies aim to restore T-cell proliferation and antitumor activity, but not all patients benefit equally. Clinical studies show that patients classified as IRS-high have significantly lower progression-free survival (PFS) and overall survival (OS) compared to IRS-negative cohorts. The assay thus helps determine whether a patient is more likely to respond to monotherapy or require combination therapy.
The EpiSwitch® CiRT is a blood-based, quantitative laboratory-developed test (LDT) designed to predict a patient’s likelihood of responding to immune checkpoint inhibitor (ICI) therapy. Immune checkpoint inhibitors such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 agents that have revolutionized oncology; however, clinical response rates vary widely, and nearly 70 percent of patients fail to benefit. The CiRT assay provides a precision-medicine approach to identify patients who are more likely to respond favorably to immunotherapy before or during treatment.
Developed by Oxford BioDynamics plc, the test is based on the proprietary EpiSwitch® platform, which evaluates the three-dimensional (3D) conformation of chromatin, an epigenetic feature that reflects gene regulatory activity. The assay measures eight chromatin conformational signatures (CCS) associated with immune-regulatory genes, including PD-1, PD-L1, and CTLA-4, that collectively indicate the immune system’s readiness to respond to checkpoint inhibition.
In multi-center validation studies across 15 cancer types, the EpiSwitch CiRT demonstrated 91% sensitivity, 81% specificity, with 84% overall accuracy, with a positive predictive value (PPV) of 67% and a negative predictive value (NPV) of 96%. The test can be performed at any point during a patient’s treatment, and it is not limited to a single tumor type or therapeutic agent, and is intended to complement, rather than replace, other clinical and pathological assessments of immunotherapy eligibility.
- For the characterization of PDL-1 gene expression
- For predicting the benefit from anti-PD-1/PDL-1 immunotherapy
- Helpful in comparing the treatment benefit from monotherapy and combination therapy
- Predicts the likelihood of clinical response to immune checkpoint inhibitors
- Complements PD-L1 IHC, TMB, and MSI testing for comprehensive immunotherapy assessment.
Strata Select™
- A high immunotherapy response score indicates that the patient can be benefitted with anti-PD-1/PD-L1 monotherapy.
- A low immunotherapy response score indicates that the patient is less likely to be benefitted with the anti-PD-1/PD-L1 monotherapy and may require other immuno/combination treatment.
EpiSwitch® CiRT
- Low probability: Indicates low likelihood of response to a range of ICI therapy. The results should be interpreted with other clinical features.
- High probability: Indicates high likelihood of response to a range of ICI therapy. Patients with this result have a high chance of benefitting from ICI as compared to chemotherapy or radiation therapy.
High Likelihood of Response
Formalin fixed paraffin embedded (FFPE) tissues, additionally, whole blood may be required.
Fixed tissues are stable at room temperature for longer time .
Whole blood, EDTA, 3 mL, Transport and store frozen. Follow Oxford BioDynamics’ specimen transport and storage guidelines.
- Cancer Res Commun. 2023 Jul 25;3(7):1335-1349. [PMID: 37497337]
- Commun Med (Lond). 2023 Feb 7;3(1):14. [PMID: 36750617]
- Cancers (Basel). 2025 Feb 4;17(3):521. [PMID: 39941889]
- Cancers (Basel). 2025 Jun 29;17(13):2193. [PMID: 40647492]
- JAMA Netw Open. 2019 Jul 3;2(7):e196879. [PMID: 31290993]
- Int J Cancer. 2020 Jun 1;146(11):3087-3097. [PMID: 31479512]
- Annu Rev Pathol. 2021 Jan 24;16:223-249. [PMID: 33197221]
- Cancers (Basel). 2023 May 10;15(10):2696. [PMID: 37345033]